Last $3.44 USD
Change Today +0.09 / 2.69%
Volume 32.7K
TROV On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

trovagene inc (TROV) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/13 - $10.27
52 Week Low
07/9/14 - $3.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TROVAGENE INC (TROV)

trovagene inc (TROV) Related Bloomberg News

View More Bloomberg News

trovagene inc (TROV) Related Businessweek News

No Related Businessweek News Found

trovagene inc (TROV) Details

Trovagene, Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology. Its technology is used in the detection and monitoring of diseases in various medical disciplines, primarily the management of cancer treatment. The company’s proprietary urine-based molecular diagnostic tests are used to detect cell-free DNA and RNA originating from normal and diseased cell death that can be isolated and detected from urine. Its technology is applied in various testing, such as tumor mutation detection and monitoring, infectious disease monitoring, transplantation monitoring, and prenatal genetic diagnostics. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

21 Employees
Last Reported Date: 03/17/14
Founded in 1999

trovagene inc (TROV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $533.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $333.8K
Chief Scientific Officer
Total Annual Compensation: $269.7K
Compensation as of Fiscal Year 2013.

trovagene inc (TROV) Key Developments

Trovagene, Inc. Secures $15 Million in Debt Financing from Silicon Valley Bank and Oxford Finance LLC

Trovagene, Inc. announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the company's precision cancer monitoring platform.

TrovaGene, Inc. Enters into Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute

Trovagene, Inc. and the Northwestern Medicine Developmental Therapeutics Institute have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice. The Lurie Cancer Center and NMDTI will work with Trovagene on clinical protocols that incorporate oncogene mutation monitoring during the course of cancer treatment and will assess the impact on overall disease management and patient outcomes.

TrovaGene, Inc. Announces Clinical Collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations. A Dana-Farber oncology team, led by Jason Luke, M.D., will conduct clinical studies designed to monitor oncogene mutations in study subjects based on urinary cell-free DNA as an analytical specimen. Studies will be designed to collect data regarding the clinical status of patients, treatment effect, and long-term outcomes of therapy using Trovagene's non-invasive molecular diagnostic technology. Trovagene is engaged in numerous collaborations designed to demonstrate the clinical utility of its precision cancer monitoring platform for the detection of mutational status in cancer patients, and the assessment of tumor dynamics and treatment response over time. To date, the company has processed over 1,000 patient samples under its collaborations, and is focused on developing the clinical evidence to support broad market adoption of its technology.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TROV:US $3.44 USD +0.09

TROV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $30.82 USD +1.00
Genomic Health Inc $26.70 USD +0.54
Laboratory Corp of America Holdings $104.59 USD +0.62
Veracyte Inc $14.56 USD -0.36
View Industry Companies

Industry Analysis


Industry Average

Valuation TROV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 259.0x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 166.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TROVAGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at